FDA approves the first drug to treat inherited breast cancer U.S. controllers have affirmed the principal medicate went for ladies with cutting-edge bosom disease caused by an acquired defective quality.   The Food and Drug Administration on Friday affirmed AstraZeneca PLC’s Lynparza for patients with acquired BRCA quality transformations